Claims
- 1. A method of achieving a cytoprotective effect in a patient in need of such treatment, comprising administering to the patient an amount of a 13-thiaprostaglandin of the formula ##STR3## wherein B is --CH.sub.2 --CH.sub.2 --or --CH.dbd.CH--,
- R.sup.1 is phenyl, CH.sub.3, or NH.sub.2,
- R.sup.2 is H or CH.sub.3, and
- R.sup.3 is pentyl, hexyl, 1-methylpentyl, or 1,1-dimethylpentyl effective to achieve a cytoprotective effect but less than that required to achieve an antisecretory effect in said patient.
- 2. A method of claim 1 wherein the administration is prophylactic and the patient is not yet suffering from an abnormality treatable with a cytoprotective agent but is susceptible to such an abnormality which it is desired to prevent.
- 3. A method of claim 1 wherein the method is therapeutic and the patient is suffering from an abnormality treatable with a cytoprotective agent.
- 4. A method of claim 2 comprising co-administering to the patient a medicament which is cell tissue-irritating and a 13-thiaprostaglandin of said formula.
- 5. A method of claim 3 comprising co-administering to the patient a medicament which is cell tissue-irritating and a 13-thiaprostaglandin of said formula.
- 6. A method of claim 3 wherein the patient is suffering from a mucosa lesion of the upper gastrointestinal tract.
- 7. A method of claim 4 wherein said co-administered medicament is an irritant of the mucosa of the upper gastrointestinal tract.
- 8. A method of claim 2 wherein said abnormality to which the patient is susceptible is a peptic ulcer.
- 9. A method of claim 2 wherein said abnormality to which the patient is susceptible is gastritis.
- 10. A method of claim 4 wherein the co-administered medicament is a cytostatic agent.
- 11. A method of claim 1 wherein the daily dose is 0.01 to 3 mg.
- 12. A method of claim 1 wherein the 13-thiaprostaglandin is administered at a dosage at which it causes substantially no antisecretory effect.
- 13. A method of claim 1 wherein the 13-thiaprostaglandin is 11.alpha., 15-dihydroxy-15-methyl-9-oxo-13-thiaprostanoic acid, p-benzoylaminophenyl ester or 11.alpha., 15-dihydroxy-15,16,16-trimethyl-9-oxo-13-thiaprostanoic acid p-benzoylaminophenyl ester.
- 14. A composition of claim 13 wherein the 13-thiaprostaglandin is 11.alpha., 15-dihydroxy-15-methyl-9-oxo-13-thiaprostanoic acid, p-benzoylaminophenyl ester or 11.alpha., 15-dihydroxy-15,16,16-trimethyl-9-oxo-13-thiaprostanoic acid p-benzoylaminophenyl ester.
- 15. A method of claim 1, wherein the dosage is 0.03 to 1 mg.
- 16. A method of claim 11, wherein the dosage is 0.03 to 1 mg.
- 17. A pharmaceutical composition comprising (a) a medicament which is a cell tissue irritant and (b) an amount effective to achive a cytoprotective effect relative to that medicament of a 13-thiaprostaglandin of the formula ##STR4## wherein B is --CH.sub.2 --CH.sub.2 --or --CH.dbd.CH--,
- R.sup.1 is phenyl, CH.sub.3, or NH.sub.2,
- R.sup.2 is H or CH.sub.3, and
- R.sup.3 is pentyl, hexyl, 1-methylpentyl, or 1,1-dimethylpentyl,
- 18. A pharmaceutical composition of claim 17 wherein the cell tissue irritant is a mucosa-irritant.
- 19. A pharmaceutical composition of claim 18 wherein the mucosa-irritating medicament is acetylsalicylinc acid, indomethacin, a bile acid or salt thereof, or a corticosteriod.
- 20. A pharmaceutical composition of claim 17 wherein the tissue-irritating medicament is a chemotherapeutical agent.
Priority Claims (1)
Number |
Date |
Country |
Kind |
57-121354 |
Jul 1982 |
JPX |
|
Parent Case Info
This application is a continuation-in-part of U.S. Ser. No. 458,077, filed on Jan. 14, 1983, now abandoned and whose disclosure is incorporated by reference herein.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4309441 |
Radunz et al. |
Jan 1982 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
458077 |
Jan 1983 |
|